Streetbeat News

Revenues

MARA

Analyst ratings for Marathon Digital Holdings (NASDAQ:MARA) have varied over the past quarter, with a recent shift towards a more neutral stance. The average 12-month price target has increased to $29.00, up from $23.33, indicating a bullish outlook from some analysts despite the overall mixed sentiment. The company, focusing on cryptocurrency mining, has shown significant revenue growth and strong financial performance, with a revenue growth rate of 671.07% and a net margin of 65.55%.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:02 pm

KLAC

Analyst ratings for KLA (NASDAQ:KLAC) show varied sentiments, with recent updates indicating a shift towards more positive outlooks. The average 12-month price target has been raised to $638.53, reflecting a 12.52% increase from the previous target. Analyst actions include maintaining, raising, and announcing ratings, with price targets adjusted accordingly. KLA's financial performance shows strong profitability but faces revenue challenges and a high debt-to-equity ratio. The company is a major player in the semiconductor process control market.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:01 pm

CIVI

Civitas Resources (NYSE:CIVI) has been evaluated by 4 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is now $94.25, down 7.14% from the previous $101.50. Analyst actions include raising and lowering ratings and price targets, reflecting dynamic market conditions and company performance. Civitas Resources, an independent exploration and production company, has shown a revenue growth of 38.38% as of December 31, 2023, but faces challenges in profitability, asset utilization, and financial leverage.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:01 pm

ADI

Analog Devices (NASDAQ:ADI) has been analyzed by 11 analysts, showing a shift towards a more cautious stance with 0 bullish and 1 indifferent rating in the last 30 days, compared to more optimistic ratings 1 month ago. The 12-month price target averages at $208.55, slightly up from $208.50. Recent analyst actions include adjustments to ratings and price targets by firms such as Morgan Stanley, Oppenheimer, and Goldman Sachs, reflecting changing market dynamics and company performance. Despite this, ADI faces challenges with a -22.68% revenue decline over 3 months and below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 8:00 pm

EVBG

Everbridge (NASDAQ:EVBG) has been the subject of diverse analyst opinions over the past quarter, with recent evaluations showing a unanimous indifferent stance. The average 12-month price target for EVBG has risen 37.5% to $31.9, with analysts from Canaccord Genuity and Truist Securities raising their targets. Despite a negative revenue trend and a high debt-to-equity ratio, Everbridge's net margin and ROE outperform industry standards. The company specializes in enterprise software for critical event management, primarily serving the U.S. market.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:02 pm

AHCO

AdaptHealth (NASDAQ:AHCO) received mixed analyst ratings over the past three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for AHCO has been raised to $12.00, up 20% from the previous $10.00, with high estimates reaching $13.00. Analysts from RBC Capital, UBS, and Truist Securities have adjusted their ratings and price targets, reflecting changing market conditions and company performance. AdaptHealth, a provider of home healthcare solutions, has shown positive revenue growth and a strong net margin but faces challenges with its ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

APPN

Over the last three months, 4 analysts have provided diverse opinions on Appian (NASDAQ:APPN), with recent ratings ranging from bullish to bearish. The average 12-month price target is now $45.5, down 4.21% from the previous $47.50. Analyst actions include both upgrades and downgrades, reflecting dynamic market conditions and Appian's performance. Despite positive revenue growth of 15.53% as of December 31, 2023, Appian faces challenges in profitability, debt management, and operational efficiency compared to industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

DLTR

Four analysts have recently updated their ratings on Dollar Tree (NASDAQ:DLTR), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has been raised to $161.5, indicating a 16.19% increase from the previous target of $139.00. Analysts from Wells Fargo, Gordon Haskett, JP Morgan, and Truist Securities have adjusted their price targets and ratings, reflecting optimism about Dollar Tree's future performance. The company has demonstrated strong financial health with a revenue growth rate of 5.4% and a net margin of 2.9%, although it faces challenges with below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:01 pm

PTVE

Pactiv Evergreen (NASDAQ:PTVE) has been analyzed by 9 analysts, showing a diverse range of perspectives with an average 12-month price target of $15.94, indicating a 26.71% increase from the previous target. The company operates in foodservice and beverage cartons, facing revenue challenges but showing strong profitability and effective cost management. Analysts' ratings and price targets have been adjusted based on recent developments and financial performance.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:00 pm

CI

A comprehensive review of 12 analyst recommendations for Cigna Group (NYSE:CI) reveals a diverse range of perspectives, with the majority being bullish or somewhat bullish. The average 12-month price target for CI has been raised to $361.67, indicating a positive outlook. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance, reflecting an optimistic view of Cigna's financial health, including its market capitalization, revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 7:00 pm